CHRM3 and chronic obstructive pulmonary disease: To the best of our knowledge, there are no similar studies for revefenacin, a new muscarinic M3 receptor antagonist used for relieving COPD symptoms [58], repaglinide, an antidiabetic inhibitor of ATP-sensitive potassium channels [59], and buclizine, a sedating antihistamine [60].